IHS Chemical Week

People & Business :: Companies

BMS Extends Lonza Contract

1:43 PM MDT | March 21, 2007 | Alex Scott

Bristol-Myers Squibb (BMS) says it has agreed to extend a supply agreement with Lonza, in which Lonza will manufacture BMS’s biologic rheumatoid arthritis drug Orencia until 2014. Orencia was approved by FDA in 2005 and launched in the U.S. in February 2006. The product generated sales of $32 million in the final quarter of 2006. Lonza will produce the product at its Portsmouth, NH facility. Separately, Lonza says it has granted UCB a non-exclusive license to its glutamine synthetase (GS) gene expression system for manufacturing therapeutic recombinant...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa